### Analysis:
Merck's earnings call provided a comprehensive overview of the company's performance in 2011 and their outlook for 2012. The company reported strong financial results with a 5% increase in sales and a 10% increase in non-GAAP EPS. The management team highlighted their strategy of growing the core, expanding into key markets, and accelerating new product launches. The company also announced several new product launches and significant investments in emerging markets, particularly in China. Despite some headwinds, such as the U.S. SINGULAIR patent expiration and the annualization of the J&J settlement, the company remains optimistic about its ability to maintain its revenue and EPS levels in 2012.

### Conclusion:
The stock is likely to see a positive impact in the short term due to the strong financial performance, optimism about 2012 growth, and the company's strategic focus on innovation and emerging markets. However, the stock may face some short-term pressure due to the patent expiration of SINGULAIR and the uncertainty around the IMPROVE-IT trial.

### Rating:
1